MX2020008905A - Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. - Google Patents

Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.

Info

Publication number
MX2020008905A
MX2020008905A MX2020008905A MX2020008905A MX2020008905A MX 2020008905 A MX2020008905 A MX 2020008905A MX 2020008905 A MX2020008905 A MX 2020008905A MX 2020008905 A MX2020008905 A MX 2020008905A MX 2020008905 A MX2020008905 A MX 2020008905A
Authority
MX
Mexico
Prior art keywords
insulin
combination
therapeutic uses
analogs
glucokinase activators
Prior art date
Application number
MX2020008905A
Other languages
English (en)
Inventor
Lopez Maria Carmen Valcarce
Jennifer L R Freeman
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of MX2020008905A publication Critical patent/MX2020008905A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Métodos para utilizar activadores de glucoquinasa (GK) generalmente se divulgan en la presente, en particular en combinación con insulinas o análogos de insulina. En algunos aspectos, la divulgación proporciona métodos para tratar la diabetes tipo 1 que incluye la administración de un activador GK en combinación con insulinas o análogos de insulina. Los usos de los activadores GK como un medicamento tal y como se divulga en la presente, así como la fabricación de un medicamento para dichos usos.
MX2020008905A 2018-06-12 2019-06-10 Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. MX2020008905A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862683772P 2018-06-12 2018-06-12
US201962857753P 2019-06-05 2019-06-05
PCT/US2019/036227 WO2019241089A1 (en) 2018-06-12 2019-06-10 Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

Publications (1)

Publication Number Publication Date
MX2020008905A true MX2020008905A (es) 2020-12-03

Family

ID=67297247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008905A MX2020008905A (es) 2018-06-12 2019-06-10 Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.

Country Status (9)

Country Link
US (3) US10952993B2 (es)
EP (1) EP3806852A1 (es)
JP (1) JP2021526130A (es)
KR (1) KR20210020866A (es)
CN (1) CN112040945A (es)
AU (1) AU2019287437A1 (es)
CA (1) CA3093025A1 (es)
MX (1) MX2020008905A (es)
WO (1) WO2019241089A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB771147A (en) 1954-06-04 1957-03-27 Merck & Co Inc Derivatives of urea
US3152136A (en) 1958-10-30 1964-10-06 Dow Chemical Co Dinitroaroyl-nu-pyridyl amides
US3067250A (en) 1959-01-26 1962-12-04 Dow Chemical Co 4-aryl, 1, 1-di propynyl-semicarbazides
US3317534A (en) 1963-10-30 1967-05-02 Chugai Pharmaceutical Co Ltd Benzamidopyrimidines
US3551442A (en) 1965-04-06 1970-12-29 Pechiney Saint Gobain Thiazole derivatives
US3424762A (en) 1966-03-07 1969-01-28 Robins Co Inc A H Certain 3-ureidopyrrolidines
ZA6706928B (es) 1967-03-23
CH493195A (de) 1968-01-23 1970-07-15 Ciba Geigy Schädlingsbekämpfungsmittel
GB1195672A (en) 1968-02-01 1970-06-17 Mobil Oil Corp Novel Urea Derivatives and Herbicides containing the same
US4175081A (en) 1968-02-01 1979-11-20 Mobil Oil Corporation 5-Substituted thiadiazole ureas
FR7428M (es) 1968-05-06 1969-11-12
CH502762A (de) 1968-07-17 1971-02-15 Agripat Sa Neue Thiadiazolyl-harnstoffe enthaltendes herbizides Mittel
BE754783A (fr) 1969-08-15 1971-02-12 May & Baker Ltd Derives thiazolyl a usage herbicide leur preparation et les compositions qui les contiennent
GB1266769A (es) 1969-08-15 1972-03-15
GB1318291A (en) 1970-04-15 1973-05-23 Shell Int Research Carboxamide derivatives and fungicidal compositions containing them
NL7106557A (es) 1970-06-15 1971-12-17
IT960595B (it) 1971-06-16 1973-11-30 Hispaco Ag Navetta per tessitura
US3887709A (en) 1971-09-16 1975-06-03 Zdzislaw Brzozowski 2-Pyrazoline-1-carboxamide sulfonamide derivatives useful as hypoglycemic agents
DE2151766C3 (de) 1971-10-14 1981-03-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-Thiazolinyl-phenoxycarbonsäureamide
US3862163A (en) 1971-10-14 1975-01-21 Schering Ag Phenoxycarboxylic acid amides
US3874873A (en) 1972-03-27 1975-04-01 Fmc Corp Herbicidal compositions based on 1,2,3-thiadiazol-5-yl ureas
IE38778B1 (en) 1973-02-02 1978-05-24 Ciba Geigy New 1,2,4-benzotriazine derivatives
AT323195B (de) 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
JPS5614643B2 (es) 1973-07-02 1981-04-06
FR2243684B1 (es) 1973-09-19 1977-01-28 Semb
PL106114B1 (pl) 1976-12-31 1979-11-30 Akad Medyczna Sposob wytwarzania nowych n-(4-/2-/pirazolo-1-karbonamido/-etylo/-benzenosulfonylo)-mocznikow
DE2712630A1 (de) 1977-03-23 1978-09-28 Bayer Ag 1,3,4-thiadiazol-2-yl-harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
DE2716324A1 (de) 1977-04-07 1978-10-12 Schering Ag 1,2,3-thiadiazol-3-in-5-yliden- harnstoffe, verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel mit wachstumsregulatorischer wirkung fuer pflanzen
JPS6033109B2 (ja) 1977-04-28 1985-08-01 塩野義製薬株式会社 尿素誘導体の合成法
US4241072A (en) 1979-01-18 1980-12-23 Merck & Co., Inc. Substituted ureas and processes for their preparation
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
IL72093A0 (en) 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives
US4694004A (en) 1984-07-09 1987-09-15 Fujisawa Pharmaceutical Co., Ltd. Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US4808722A (en) 1985-10-31 1989-02-28 Fmc Corporation Pyridinylurea N-oxide compounds and agricultural uses
JPS6456660A (en) 1987-05-11 1989-03-03 Sumitomo Chemical Co Urea derivative or its salt, production thereof and germicide for agriculture and horticulture containing said derivative or salt thereof as active ingredient
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
RU2021258C1 (ru) 1991-02-28 1994-10-15 Агролинц Агрархемикалиен ГмбХ Способ получения несимметрично дизамещенных мочевин
US5371086A (en) 1991-03-15 1994-12-06 The Green Cross Corporation Aminopyridine compounds
JPH05294935A (ja) 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
RU94046149A (ru) 1992-05-28 1996-11-27 Пфайзер Инк. (US) Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат)
WO1994014801A1 (en) 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
GB9302275D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
US5849769A (en) 1994-08-24 1998-12-15 Medivir Ab N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
US5556969A (en) 1994-12-07 1996-09-17 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives
US6579314B1 (en) 1995-03-10 2003-06-17 C.R. Bard, Inc. Covered stent with encapsulated ends
AU6112896A (en) 1995-06-07 1996-12-30 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
EP0885890A1 (en) 1996-02-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US5846985A (en) 1997-03-05 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6268384B1 (en) 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
KR20010031912A (ko) 1997-11-10 2001-04-16 스티븐 비. 데이비스 벤조티아졸 단백질 티로신 키나제 억제제
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
CA2303781A1 (en) 1997-11-14 1999-05-27 Kowa Company, Ltd. Novel amide compounds and drugs containing the same
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
NZ505844A (en) 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2000026186A1 (fr) 1998-11-02 2000-05-11 Welfide Corporation Composes de pyrrolidine et leur utilisation medicinale
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
JP2002539119A (ja) 1999-03-08 2002-11-19 バイエル アクチェンゲゼルシャフト チアゾリルウレア誘導体および抗ウイルス剤としてのそれらの使用
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
HUP0200396A3 (en) 1999-03-29 2003-04-28 Hoffmann La Roche Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
USRE40876E1 (en) 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
CN1391473A (zh) 1999-06-30 2003-01-15 第一制药株式会社 Vla－4抑制剂化合物
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
CN1238343C (zh) 1999-09-09 2006-01-25 组合化学工业株式会社 嘧啶衍生物及含有该衍生物的除草剂
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
ATE286036T1 (de) 2000-05-03 2005-01-15 Hoffmann La Roche Heteroaromatische alkynylphenyl-verbindungen als glukokinase-aktivatoren
JP3842131B2 (ja) 2000-05-03 2006-11-08 エフ．ホフマン−ラ ロシュ アーゲー ヒダントイン含有グルコキナーゼ活性化物質
ES2230309T3 (es) 2000-05-08 2005-05-01 F. Hoffmann-La Roche Ag Fenilacetamidas sustituidas y su empleo con ativadores de qucokinasa.
ES2307623T3 (es) 2000-05-08 2008-12-01 F. Hoffmann-La Roche Ag Activadores de fenilamida glucokinasa para-amina sustituida.
KR20030017569A (ko) 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
AU2001287600B2 (en) 2000-07-20 2006-07-13 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
WO2002046173A1 (en) 2000-12-06 2002-06-13 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
EE200300362A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
DE60208630T2 (de) 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
JP2004536845A (ja) 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介疾患の治療方法
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
DE60221627D1 (de) 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
AU2002351748B2 (en) 2001-12-21 2009-07-09 Novo Nordisk A/S Amide derivatives as GK activators
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
EP1600442B1 (en) 2003-02-26 2018-01-17 Msd K.K. Heteroarylcarbamoylbenzene derivative
US7111188B2 (en) 2003-07-31 2006-09-19 International Business Machines Corporation Dynamically configurable fault tolerance in autonomic computing with multiple service points
TW200505894A (en) 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative
US7029649B2 (en) 2003-08-26 2006-04-18 General Motors Corporation Combinations of hydrogen storage materials including amide/imide
AU2003269484A1 (en) 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
WO2005086145A1 (en) 2004-02-26 2005-09-15 Koninklijke Philips Electronics N.V. Multiple-spiral hybrid disc for e-book applications
JP4334374B2 (ja) 2004-03-05 2009-09-30 株式会社東芝 被ばく線量評価方法、被ばく線量評価システムおよび被ばく線量評価プログラム
MXPA06011328A (es) 2004-04-02 2006-12-15 Vertex Pharma Azaindoles utiles como inhibidotes de roca y otras proteinas cinasas.
EP1758611A2 (en) 2004-06-17 2007-03-07 Novo Nordisk A/S Use of liver-selective glucokinase activators
KR20070073879A (ko) 2004-10-07 2007-07-10 스템 셀 테라퓨틱스 코포레이션 임신 관련 화합물의 투여를 통한 다능성 줄기 세포의증식을 자극하는 방법
US20060246141A1 (en) 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US20100028439A1 (en) 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
EP1904466A1 (en) 2005-07-08 2008-04-02 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
WO2007006761A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkylcarbamoyl ureas as glucokinase activators
CN101263131B (zh) 2005-07-14 2013-04-24 特兰斯特克药品公司 脲葡糖激酶活化剂
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
JP2010515701A (ja) 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
WO2009054251A1 (ja) 2007-10-25 2009-04-30 Sanyo Electric Co., Ltd. 発電装置
AU2009246167B2 (en) 2008-05-16 2013-08-22 Takeda California, Inc. Glucokinase activators
US8577077B2 (en) 2008-05-22 2013-11-05 Yuvad Technologies Co., Ltd. System for identifying motion video/audio content
WO2010107610A1 (en) 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
UA111742C2 (uk) 2009-04-16 2016-06-10 Тайсо Фармасьютікал Ко., Лтд. Фармацевтичні композиції
WO2011025270A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제
AU2011258460B2 (en) 2010-05-26 2015-02-19 Vtv Therapeutics Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
EP2392575A1 (en) 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
SG11201406987UA (en) 2012-05-17 2014-12-30 Transtech Pharma Llc Glucokinase activator compositions for the treatment of diabetes
JP6016621B2 (ja) 2012-12-26 2016-10-26 花王株式会社 清掃具のジョイント構造
MX2015011110A (es) 2013-03-04 2015-10-29 Vtv Therapeutics Llc Composiciones solidas que comprenden un activador de glucoquinasa y metodos para elaborar y utilizar las mismas.
EP2964198A2 (en) 2013-03-04 2016-01-13 vTv Therapeutics LLC Stable glucokinase activator compositions
JP6102611B2 (ja) 2013-07-31 2017-03-29 セイコーエプソン株式会社 液体噴射装置及びワイピング方法
US10696424B2 (en) 2016-06-29 2020-06-30 Lockheed Martin Corporation Spacecraft structures incorporating graphene and operation thereof
US11266630B2 (en) 2016-12-15 2022-03-08 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
KR20230048502A (ko) 2020-06-08 2023-04-11 브이티브이 테라퓨틱스 엘엘씨 ｛2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐｝-아세트산의 염 또는 공결정 및 그의 용도
JP2023530785A (ja) 2020-06-08 2023-07-19 ブイティーブイ・セラピューティクス・エルエルシー ｛２－［３－シクロヘキシル－３－（ｔｒａｎｓ－４－プロポキシ－シクロヘキシル）－ウレイド］－チアゾール－５－イルスルファニル｝－酢酸の結晶形およびその使用

Also Published As

Publication number Publication date
US11833136B2 (en) 2023-12-05
CA3093025A1 (en) 2019-12-19
KR20210020866A (ko) 2021-02-24
AU2019287437A1 (en) 2020-09-10
US20200147052A1 (en) 2020-05-14
JP2021526130A (ja) 2021-09-30
EP3806852A1 (en) 2021-04-21
US10952993B2 (en) 2021-03-23
US20210169857A1 (en) 2021-06-10
CN112040945A (zh) 2020-12-04
WO2019241089A1 (en) 2019-12-19
US20210169858A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MX2018005588A (es) Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.
PH12020500555A1 (en) Esketamine for the treatment of depression
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
WO2015106269A3 (en) Rapid action insulin formulations and pharmaceutical delivery systems
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
EP3575314A3 (en) Glucagon derivatives
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
PH12018500690A1 (en) Novel insulin analogs and use thereof
MX2013013242A (es) Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal.
MX368387B (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
CR20190523A (es) Compuesto de insulina acilada
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MX2020008387A (es) Usos terapeuticos de agonistas glp1r.
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
PH12020500374A1 (en) Treatment regimens
MX2020008905A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
WO2014193832A3 (en) Glucagon-like peptide 1 (glp-1) receptor modulators and uses thereof in regulating blood glucose levels
MX369090B (es) Sultiame para el tratamiento de apnea del sueño.
MX2022001647A (es) Terapia de combinacion con vildagliptina y metformina.